Brain-derived erythropoietin protects from focal cerebral ischemia by dual activation of ERK-1/-2 and Akt pathways

FASEB Journal

Volumn 19, Issue 14, 2005, Pages 2026-2028

  Kilic, Ertugrul ^a,c   Kilic, Ülkan ^a   Soliz, Jorge ^b   Bassetti, Claudio L ^a   Gassmaim, Max ^b   Hermann, Dirk M ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; DIMETHYL SULFOXIDE; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NEURONAL NITRIC OXIDE SYNTHASE; PROTEIN BCL XL; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE 1; WORTMANNIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ANGIOGRAPHY; BRAIN BLOOD FLOW; BRAIN CORTEX; BRAIN EDEMA; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN PROTECTION; CLINICAL TRIAL; CORPUS STRIATUM; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LASER DOPPLER FLOWMETRY; MOUSE; NERVE CELL LESION; NEUROPROTECTION; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALIA; MUS MUSCULUS;

EID: 28744455284     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.05-3941fje     Document Type: Article

References (37)

1. Gassmann, M., Heinicke, K., Soliz, J., and Ogunshola, O. O. (2003) Non-erythroid functions of erythropoietin. Adv. Exp. Med. Biol. 543, 323–330
2. Grimm, C., Hermann, D. M., Bogdanova, A., Hotop, S., Kilic, Ü., Wenzel, A., Kilic, E., and Gassmann, M. (2005) Neuroprotection by hypoxic preconditioning: HIF-1 and erythropoietin protect from retinal degeneration. Semin. Cell Dev. Biol., 16, 531-538
3. Brines, M. L., Ghezzi, P., Keenan, S., Agnello, D., de Lanerolle, N. C., Cerami, C., Itri, L. M., and Cerami, A. (2000) Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl. Acad. Sci. USA 97, 10,526–10,531
4. Sirén, A. L., Fratelli, M., Brines, M., Goemans, C., Casagrande, S., Lewczuk, P., Keenan, S., Gleiter, C., Pasquali, C., Capobianco, A., et al. (2001) Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc. Natl. Acad. Sci. USA 98, 4044–4049
5. Celik, M., Gokmen, N., Erbayraktar, S., Akhisaroglu, M., Konakc, S., Ulukus, C., Genc, S., Genc, K., Sagiroglu, E., Cerami, A., et al. (2002) Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc. Natl. Acad. Sci. USA 99, 2258–2263
6. Grimm, C., Wenzel, A., Groszer, M., Mayser, H., Seeliger, M., Samardzija, M., Bauer, C., Gassmann, M., and Reme, C. E. (2002) HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat. Med. 8, 718–724
7. Grimm, C., Wenzel, A., Stanescu, D., Samardzija, M., Hotop, S., Groszer, M., Naash, M., Gassmann, M., and Remé, C. (2004) Constitutive overexpression of human erythropoietin protects the mouse retina against induced but not inherited retinal degeneration. J. Neurosci. 24, 5651–5658
8. Kilic, Ü., Kilic, E., Soliz, J., Bassetti, C. L., Gassmann, M., and Hermann, D. M. (2005) Erythropoietin protects from axotomy-induced degeneration of retinal ganglion cells by activating ERK-1/-2. FASEB J. 19, 249–251
9. Ehrenreich, H., Hasselblatt, M., Dembowski, C., Cepek, L., Lewczuk, P., Stiefel, M., Rustenbeck, H. H., Breiter, N., Jacob, S., Knerlich, F., et al. (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. 8, 495–505
10. Hudson, J. Q., and Sameri, R. M. (2002) DarbEpoetin alfa, a new therapy for the management of anemia of chronic kidney disease. Pharmacotherapy 22, 141S–149S
11. Macdougall, I. C. (2003) Erythropoietin and renal failure. Curr. Hematol. Rep. 2, 459–464
12. Brines, M., Grasso, G., Fiordaliso, F., Sfacteria, A., Ghezzi, P., Fratelli, M., Latini, R., Xie, Q.W., Smart, J., Su-Rick, C.J., Pobre, E., Diaz, D., Gomez, D., Hand, C., Coleman, T., and Cerami, A. (2004) Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc. Natl. Acad. Sci. USA. 101, 14,907-14,912.
13. Ruschitzka, F. T., Wenger, R. H., Stallmach, T., Quaschning, T., de Wit, C., Wagner, K., Labugger, R., Kelm, M., Noll, G., Rülicke, T., et al. (2000) Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc. Natl. Acad. Sci. USA 97, 11,609–11,613
14. Wiessner, C., Allegrini, P. R., Ekatodramis, D., Jewell, U. R., Stallmach, T., and Gassmann, M. (2001) Increased cerebral infarct volumes in polyglobulic mice overexpressing erythropoietin. J. Cereb. Blood Flow Metab. 21, 857–864
15. Kilic, E., Dietz, G. P., Hermann, D. M., and Bähr, M. (2002) Intravenous TAT-Bcl-Xl is protective after middle cerebral artery occlusion in mice. Ann. Neurol. 52, 617–622
16. Wang, Y., Kilic, E., Kilic, Ü., Weber, B., Bassetti, C. L., Marti, H. H., and Hermann, D. M. (2005) VEGF overexpression induces post-ischaemic neuroprotection, but facilitates haemodynamic steal phenomena. Brain 128, 52–63
17. Hermann, D. M., Kilic, E., Hata, R., Hossmann, K. A., and Mies, G. (2001a) Relationship between metabolic dysfunctions, gene responses and delayed cell death after mild focal cerebral ischemia in mice. Neuroscience 104, 947–955
18. Hermann, D. M., Kilic, E., Kügler, S., Isenmann, S., and Bähr, M. (2001b) Adenovirusmediated GDNF and CNTF pretreatment protects against striatal injury following transient middle cerebral artery occlusion in mice. Neurobiol. Dis. 8, 655–666
19. Maeda, K., Hata, R., and Hossmann, K. A. (1999) Regional metabolic disturbances and cerebrovascular anatomy after permanent middle cerebral artery occlusion in C57black/6 and SV129 mice. Neurobiol. Dis. 6, 101–108
20. Wenger, R. H., Marti, H. H., Bauer, C., and Gassmann, M. (1998) Optimal erythropoietin expression in human hepatoma cell lines requires activation of multiple signalling pathways. Int. J. Mol. Med. 2, 317–324
21. Digicaylioglu, M., Bichet, S., Marti, H. H., Wenger, R. H., Rivas, L. A., Bauer, C., and Gassmann, M. (1995) Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc. Natl. Acad. Sci. USA 92, 3717–3720
22. Marti, H. H., Wenger, R. H., Rivas, L. A., Straumann, U., Digicaylioglu, M., Henn, V., Yonekawa, Y., Bauer, C., and Gassmann, M. (1996) Erythropoietin gene expression in human, monkey and murine brain. Eur. J. Neurosci. 8, 666–676
23. Höpfl, G., Ogunshola, O., and Gassmann, M. (2004) HIFs and tumors - causes and consequences. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286, R608–R623
24. Alessandrini, A., Namura, S., Moskowitz, M. A., and Bonventre, J. V. (1999) MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia. Proc. Natl. Acad. Sci. USA 96, 12,866–12,869
25. Han, B. H., and Holtzman, D. M. (2000) BDNF protects the neonatal brain from hypoxicischemic injury in vivo via the ERK pathway. J. Neurosci. 20, 5775–5781
26. Chong, Z. Z., Lin, S. H., Kang, J. Q., and Maiese, K. (2003a) Erythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3, and 8. J. Neurosci. Res. 71, 659–669
27. Ruscher, K., Freyer, D., Karsch, M., Isaev, N., Megow, D., Sawitzki, B., Priller, J., Dirnagl, U., and Meisel, A. (2002) Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J. Neurosci. 22, 10,291–10,301
28. Chong, Z. Z., Kang, J. Q., and Maiese, K. (2003b) Apaf-1, Bcl-xL, cytochrome c, and caspase-9 form the critical elements for cerebral vascular protection by erythropoietin. J. Cereb. Blood Flow Metab. 23, 320–330
29. Nagata, Y., Takahashi, N., Davis, R. J., and Todokoro, K. (1998) Activation of p38 MAP kinase and JNK but not ERK is required for erythropoietin-induced erythroid differentiation. Blood 92, 1859–1869
30. Jacobs-Helber, S. M., Ryan, J. J., and Sawyer, S. T. (2000) JNK and p38 are activated by erythropoietin (Epo) but are not induced in apoptosis following Epo withdrawal in Epodependent HCD57 cells. Blood 96, 933–940
31. Irving, E. A., and Bamford, M. (2002) Role of mitogen- and stress-activated kinases in ischemic injury. J. Cereb. Blood Flow Metab. 22, 631–647
32. Okuno, S., Saito, A., Hayashi, T., and Chan, P. H. (2004) The c-Jun N-terminal protein kinase signaling pathway mediates Bax activation and subsequent neuronal apoptosis through interaction with Bim after transient focal cerebral ischemia. J. Neurosci. 24, 7879–7887
33. Hirt, L., Badaut, J., Thevenet, J., Granziera, C., Regli, L., Maurer, F., Bonny, C., and Bogousslavsky, J. (2004) D-JNKI1, a cell-penetrating c-Jun-N-terminal kinase inhibitor, protects against cell death in severe cerebral ischemia. Stroke 35, 1738–1743
34. Kilic, Ü., Kilic, E., Reiter, R. J., Bassetti, C., and Hermann, D. M. (2005b) Signal transduction pathways involved in melatonin-induced neuroprotection after focal cerebral ischemia in mice. J. Pineal Res. 38, 67–71
35. Squadrito, F., Altavilla, D., Squadrito, G., Campo, G. M., Arlotta, M., Quartarone, C., Saitta, A., and Caputi, A. P. (1999) Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock. Br. J. Pharmacol. 127, 482–488
36. Dalkara, T., and Moskowitz, M. A. (1994) The complex role of nitric oxide in the pathophysiology of focal cerebral ischemia. Brain Pathol. 4, 49–57
37. Leist, M., Ghezzi, P., Grasso, G., Bianchi, R., Villa, P., Fratelli, M., Savino, C., Bianchi, M., Nielsen, J., Gerwien, J., et al. (2004) Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305, 239–242